-
In this issue: Examining the three arms of the ACCORD trial; and FDA Actions: clopidogrel, dexlansoprazole, and tamsulosin.
-
This clinical study was carried out to test the hypothesis that acetazolamide (Diamox®) would correct metabolic alkalosis and facilitate weaning in intubated patients with severe chronic obstructive pulmonary disease (COPD) who had elevated serum bicarbonate and were alkalemic.
-
Endotracheal tubes (ETTs) coated with antimicrobial substances can reduce bacterial adhesion on the tube, block biofilm formation, and reduce bacterial burden in tracheal secretions. Various antimicrobial agents have been employed for this purpose.
-
The role of statins in treatment of dyslipidemia is well established. There are, however, limitations of statins: Residual risk is substantial, not all persons can tolerate statins, and, even with full-dose statin treatment, some patients do not achieve lipid goals.
-
-
FDA is reviewing safety of TZDs; SSRI use with tamoxifen; Metformin smells like fish; FDA Actions.
-
Haiti is one of the poorer countries in the world, with the highest per-capita rate of tuberculosis (TB) in Latin America and the Caribbean.
-
A once-daily controlled-release formulation of hydromorphone has been approved by the FDA.
-
The ECG shown above was obtained from a 54-year-old woman with shortness of breath. What pulmonary findings on ECG might explain her symptoms?
-
Middle-aged men who are overweight or obese, with or without the metabolic syndrome, are at increased risk for cardiovascular events and total death.